Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Abstract We conducted an institutional study to compare the clinical and pathological efficacy between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle albumin–bound paclitaxel plus gemcitabine (nab‐P/G) for borderline resectable pancreatic cancer (BRPC) and locally advanced...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Adam R. Wolfe, Dhivya Prabhakar, Vedat O. Yildiz, Jordan M. Cloyd, Mary Dillhoff, Laith Abushahin, Dayssy Alexandra Diaz, Eric D. Miller, Wei Chen, Wendy L. Frankel, Anne Noonan, Terence M. Williams
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley 2020-07-01
Seri Bilgileri:Cancer Medicine
Konular:
chemotherapy
FOLFIRINOX
nab‐paclitaxel
neoadjuvant
pancreatic cancer
radiation
Online Erişim:https://doi.org/10.1002/cam4.3075
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller